CYP2D6 predicted metabolizer status and safety in adult patients with attention‐deficit hyperactivity disorder participating in a large placebo‐controlled atomoxetine maintenance of response clinical trial

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 10, 2015-10 ,pp. : 1167-1174

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of Patients' Preferences: Direct Assessment and Discrete-Choice Experiment in Therapy of Adults with Attention-Deficit Hyperactivity Disorder

By Mühlbacher Axel C.   Nübling Matthias  

The Patient: Patient-Centered Outcomes Research, Vol. 3, Iss. 4, 2010-12 ,pp. : 285-294

Adis International

Access to resources Recommend Favorite

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)

By Prasad Suyash   Harpin Val   Poole Lynne   Zeitlin Harry   Jamdar Saroj   Puvanendran Kanagasabai    

Current Medical Research and Opinion, Vol. 23, Iss. 2, 2007-02 ,pp. : 379-394

Informa Healthcare

Access to resources Recommend Favorite

Attention‐Deficit Hyperactivity Disorder and Long‐QT Syndrome: Risky Business

By  

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, Vol. 26, Iss. 10, 2015-10 ,pp. : 1045-1047

John Wiley & Sons Inc

Access to resources Recommend Favorite

Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations

By Lloyd Andrew  

The Patient: Patient-Centered Outcomes Research, Vol. 4, Iss. 4, 2011-12 ,pp. : 247-257

Adis International

Access to resources Recommend Favorite